U.S. FDA Orders Dainippon Sumitomo Unit To Lower Lunesta Dosage
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA ordered Dainippon Sumitomo Pharma's U.S. subsidiary to halve the recommended dosage of its Lunesta (eszopiclone) sleeping pill and to change its label to reflect that.